Federico M Asch1, Paul A Grayburn2, Robert J Siegel3, Saibal Kar3, D Scott Lim4, Jonathan G Zaroff5, Jacob M Mishell5, Brian Whisenant6, Michael J Mack7, JoAnn Lindenfeld8, William T Abraham9, Gregg W Stone10, Neil J Weissman11. 1. Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, DC. Electronic address: federico.asch@medstar.net. 2. Baylor University Medical Center, Baylor Heart and Vascular Institute, Dallas, Texas. 3. Cedars-Sinai Smidt Heart Institute, Los Angeles, California. 4. Division of Cardiology, University of Virginia, Charlottesville, Virginia. 5. Kaiser Permanente-San Francisco Hospital, San Francisco, California. 6. Intermountain Medical Center, Murray, Utah. 7. Baylor Scott & White Heart and Vascular Hospital, Plano, Texas. 8. Advanced Heart Failure, Vanderbilt Heart and Vascular Institute, Nashville, Tennessee. 9. Departments of Medicine, Physiology, and Cell Biology, Division of Cardiovascular Medicine, and the Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio. 10. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York; The Cardiovascular Research Foundation, New York, New York. 11. Cardiovascular Core Laboratories, MedStar Health Research Institute, Washington, DC.
Abstract
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart failure (HF) and moderate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated withtranscatheter mitral valve repair (TMVr) through leaflet approximation had reduced rates of HF hospitalization and mortality compared with guideline-directed medical therapy (GDMT) alone. OBJECTIVES: The purpose of this study was to describe the echocardiographic patient qualification process for the COAPT trial, baseline echocardiographic characteristics, changes over time, and the interaction between treatment group and echocardiographic parameters on clinical outcomes. METHODS: A novel echocardiographic algorithm was implemented for grading mitral regurgitation severity during the screening process. Standardized echocardiograms were obtained at baseline and during regular follow-up intervals through 2 years, and were analyzed by a core laboratory. RESULTS: A total of 614 patients were randomized to TMVr plus maximally tolerated GDMT or GDMT alone. Mean baseline leftventricular (LV) ejection fraction was 31.3 ± 9.3%, LV end-diastolic volume was 192.7 ± 71 ml, and effective regurgitant orifice area was 0.41 ± 0.15 cm2. The beneficial effect of TMVr compared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity of LV dysfunction, LV dilatation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitation characteristics. The LV ejection fraction decreased and the LV volumes progressively increased in both groups during follow-up, although less after TMVr (p < 0.05). CONCLUSIONS: HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
RCT Entities:
BACKGROUND: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart failure (HF) and moderate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation had reduced rates of HF hospitalization and mortality compared with guideline-directed medical therapy (GDMT) alone. OBJECTIVES: The purpose of this study was to describe the echocardiographic patient qualification process for the COAPT trial, baseline echocardiographic characteristics, changes over time, and the interaction between treatment group and echocardiographic parameters on clinical outcomes. METHODS: A novel echocardiographic algorithm was implemented for grading mitral regurgitation severity during the screening process. Standardized echocardiograms were obtained at baseline and during regular follow-up intervals through 2 years, and were analyzed by a core laboratory. RESULTS: A total of 614 patients were randomized to TMVr plus maximally tolerated GDMT or GDMT alone. Mean baseline left ventricular (LV) ejection fraction was 31.3 ± 9.3%, LV end-diastolic volume was 192.7 ± 71 ml, and effective regurgitant orifice area was 0.41 ± 0.15 cm2. The beneficial effect of TMVr compared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity of LV dysfunction, LV dilatation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitation characteristics. The LV ejection fraction decreased and the LV volumes progressively increased in both groups during follow-up, although less after TMVr (p < 0.05). CONCLUSIONS:HFpatients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
Authors: Jakob Ledwoch; Carmen Fellner; Petra Hoppmann; Ruth Thalmann; Hans Kossmann; Michael Dommasch; Ralf Dirschinger; Anja Stundl; Karl-Ludwig Laugwitz; Christian Kupatt Journal: Int J Cardiovasc Imaging Date: 2020-01-13 Impact factor: 2.357
Authors: Toby Rogers; Adam B Greenbaum; Vasilis C Babaliaros; Jason R Foerst; Jaffar M Khan; Christopher G Bruce; Annette M Stine; Lowell F Satler; Emily Perdoncin; Patrick T Gleason; John C Lisko; Xin Tian; Rui Miao; Vandana Sachdev; Marcus Y Chen; Robert J Lederman Journal: JACC Cardiovasc Interv Date: 2022-06-27 Impact factor: 11.075
Authors: Philippe B Bertrand; Yasufumi Nagata; Mayooran Namasivayam; Robert A Levine Journal: J Am Soc Echocardiogr Date: 2020-08-24 Impact factor: 5.251
Authors: Tomás Benito-González; Xavier Freixa; Cosmo Godino; Maurizio Taramasso; Rodrigo Estévez-Loureiro; Daniel Hernandez-Vaquero; Ana Serrador; Luis Nombela-Franco; David Grande-Prada; Ignacio Cruz-González; Rodolfo San Antonio; Michele Galasso; Mara Gavazzoni; Carmen Garrote; Antonio Portolés-Hernández; Pablo Avanzas; Felipe Fernández-Vázquez; Isaac Pascual Journal: Ann Transl Med Date: 2020-08